The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans
Open accessAbstract
BACKGROUND Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability, and better reproducibility of human papillomavirus (HPV)-based screening compared to conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results. OBJECTIVES We summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries. SOURCES Data were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites. CONTENT As of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden, and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programs. Generally, implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries. IMPLICATIONS HPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
HPV Screening for Cervical Cancer in Rural India
Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., Hingmire, S., Malvi, S. G., Thorat, R., Kothari, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808516 · Cited by 1,321
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Arbyn, M., Smith, S. B., Temin, S., Sultana, F., & Castle, P. (2018) · BMJ · doi:10.1136/bmj.k4823 · Cited by 1,103
Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897
Self-citationMeijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692
Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
Rijksinstituut voor Volksgezondheid en Milieu
Maas, R., Fischer, P. H., Wesseling, J., & Cassee, F. R. (2015) · Cited by 411
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275
Self-citationGage, J. C., Schiffman, M., Katki, H. A., Castle, P. E., Fetterman, B., Wentzensen, N., Poitras, N. E., Lorey, T., Cheung, L. C., & Kinney, W. K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju153 · Cited by 258
von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., et al. (2015) · Papillomavirus Research · doi:10.1016/j.pvr.2015.06.006 · Cited by 253
Basu, P., Ponti, A., Anttila, A., Ronco, G., Senore, C., Vale, D. B., Segnan, N., Tomatis, M., Soerjomataram, I., Primic Žakelj, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31043 · Cited by 251
Primary cervical screening with high risk human papillomavirus testing: observational study
Rebolj, M., Rimmer, J., Denton, K., Tidy, J., Mathews, C., Ellis, K., Smith, J., Evans, C., Giles, T., Frew, V., et al. (2019) · BMJ · doi:10.1136/bmj.l240 · Cited by 172
VALGENT: a protocol for clinical validation of human papillomavirus assays
Arbyn, M., Depuydt, C., Benoy, I., Bogers, J., Cuschieri, K., Schmitt, M., Pawlita, M., Geraets, D., Heard, I., Gheit, T., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.09.014 · Cited by 157
Self-citationCommercially available molecular tests for human papillomaviruses (HPV): 2015 update
Poljak, M., Kocjan, B. J., Oštrbenk, A., & Seme, K. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.10.023 · Cited by 133
Self-citationDijkstra, M. G., van Zummeren, M., Rozendaal, L., van Kemenade, F. J., Helmerhorst, T. J. M., Snijders, P. J. F., Meijer, C. J. L. M., & Berkhof, J. H. (2016) · BMJ · doi:10.1136/bmj.i4924 · Cited by 128
Gültekin, M., Karaca, M. Z., Küçükyıldız, İ. A., Dundar, S., Boztaş, G., Turan, S. H., Hacikamiloğlu, E., Murtuza, K., Keskinkılıç, B., & Şencan, İ. (2017) · International Journal of Cancer · doi:10.1002/ijc.31212 · Cited by 115
Polman, N. J., Snijders, P. J. F., Kenter, G. G., Berkhof, J. H., & Meijer, C. J. L. M. (2018) · Preventive Medicine · doi:10.1016/j.ypmed.2018.12.021 · Cited by 106
Malagón, T., Kulasingam, S., Mayrand, M., Ogilvie, G. S., Smith, L. M., Bouchard, C., Gotlieb, W. H., & Franco, E. L. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30536-9 · Cited by 69
Ronco, G., Zappa, M., Franceschi, S., Tùnesi, S., Caprioglio, A., Confortini, M., Mistro, A. D., Carozzi, F., Segnan, N., Zorzi, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.008 · Cited by 49
Recomendaciones de prevención del cáncer. Actualización PAPPS 2018
Marzo‐Castillejo, M., Vallespín, C. V., Bellas-Beceiro, B., Bartolomé-Moreno, C., Melús-Palazón, E., Vilarrubí-Estrella, M., & Nuin-Villanueva, M. (2018) · Atención Primaria · doi:10.1016/s0212-6567(18)30362-7 · Cited by 44
Guía de cribado del cáncer de cuello de útero en España, 2014
Torné, A., Saladrigues, M. D. P., Cusidó, M., Alameda, F., Ortiz, D. A., Piqué, X. C., Bordoy, J. C., Carreño, R. G., Troyas, R. M. G., Lloveras, B., et al. (2014) · Revista Española de Patología · doi:10.1016/s1699-8855(14)70203-x · Cited by 36
Gültekin, M., Karaca, M. Z., Küçükyıldız, İ. A., Dundar, S., Keskinkılıç, B., & Turkyilmaz, M. (2019) · Papillomavirus Research · doi:10.1016/j.pvr.2019.03.002 · Cited by 35
Veijalainen, O., Kares, S., Kujala, P. M., Vuento, R., Osuala, V., Tirkkonen, M., Luukkaala, T. H., Kholová, I., & Mäenpää, J. (2018) · Cytopathology · doi:10.1111/cyt.12652 · Cited by 28
Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.05.041 · Cited by 12
Self-citation
Cited by
Bruni, L., Serrano, B., Roura, E., Alemany, L., Cowan, M., Herrero, R., Poljak, M., Murillo, R., Broutet, N., Riley, L. M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00241-8 · Cited by 558
Self-citationCancer of the cervix uteri: 2021 update
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13865 · Cited by 554
2020 list of human papillomavirus assays suitable for primary cervical cancer screening
Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284
Self-citationCancer of the cervix uteri: 2025 update
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70277 · Cited by 58
Thomsen, L. T., Kjær, S. K., Munk, C., Ørnskov, D., & Waldstrøm, M. (2021) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.14121 · Cited by 36
Metadata
- Authors
- Maver, P. J., & Poljak, M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 26
- Issue
- 5
- Pages
- 579-583
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2974028681
- Cited by
- 301
- References
- 27
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.